Latest news with #AlembicPharmaceuticalsInc.
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details
Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 mn SI Reporter New Delhi Alembic Pharmaceuticals share price: Pharmaceuticals company Alembic Pharmaceuticals shares were trading higher on Thursday, July 3, 2025, with the scrip rising up to 2.05 per cent to hit an intraday high of ₹1,010 per share. At 11:00 AM, Alembic Pharmaceuticals share price continued to trade higher, up about 1 per cent at ₹998.95. In comparison, BSE Sensex was trading 0.33 per cent higher at 83,688.57 levels. Why did Alembic Pharmaceuticals share price rise today? Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 million. In an exchange filing, Alembic Pharmaceuticals said, 'We are pleased to inform you that Alembic Pharmaceuticals Inc., wholly-owned subsidiary of Alembic Pharmaceuticals Limited, has acquired Utility Therapeutics Ltd.' Utility Therapeutics is a pharmaceutical development company specialising in treatments for urinary tract infections (UTIs). The company is currently working on two key products. The first, Pivya, is already approved by the US Food and Drug Administration (FDA) for the treatment of uncomplicated UTIs in the US market. The second, MEC, is under development and aims to address the treatment of complicated UTIs. As a product development-focused company, Utility Therapeutics has reported minimal turnover over the past three years. Alembic Pharmaceuticals said that the acquisition will be finalised in approximately 30 days. The acquisition will allow the company to market the USFDA approved product and underdevelopment product owned by the Utility in the USA. Track Stock Market LIVE Updates Alembic Pharmaceuticals Q4 results Alembic Pharmaceuticals reported a 12 per cent year-on-year (Y-o-Y) decline in net profit in the March quarter of FY25 (Q4FY25), at ₹157 crore, despite a 17 per cent rise in net sales to ₹1,770 crore. Ebitda grew 9 per cent to ₹286 crore, with the margin at 16 per cent, while profit before tax increased 5 per cent to ₹192 crore. READ MORE About Alembic Pharmaceuticals Alembic Pharmaceuticals is one of India's leading pharmaceutical companies, with a legacy dating back to 1907. Headquartered in Vadodara, Gujarat, the company has established a strong global footprint through its fully integrated operations encompassing research, development, manufacturing, and marketing of pharmaceutical products. A publicly listed entity, Alembic Pharmaceuticals is widely recognised for its extensive portfolio of generic drugs, supported by cutting-edge R&D facilities and approvals from major regulatory bodies, including the USFDA. Its manufacturing facilities are located in Gujarat and Sikkim, while R&D centres in Vadodara, Hyderabad, and New Jersey drive innovation and development. Alembic's global reach is further strengthened by its subsidiaries, Alembic Pharmaceuticals Inc. and Alembic Global Holding SA, positioning the company as a trusted provider of both branded and generic medicines worldwide.
Business Standard
a day ago
- Business
- Business Standard
Alembic Pharmaceuticals announces acquisition of Utility Therapeutics
Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved. Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). -Pivya is an FDA approved product to treat uncomplicated UTIs in the US market. -MEC is a product in development for treatment of the complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years.
Business Upturn
a day ago
- Business
- Business Upturn
Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence
Alembic Pharmaceuticals Inc., the wholly owned US subsidiary of Alembic Pharmaceuticals Limited, has announced the acquisition of UK-based Utility Therapeutics Ltd. This strategic move marks Alembic's entry into the branded anti-infective segment in the United States, particularly focusing on treatments for urinary tract infections (UTIs). Utility Therapeutics is engaged in developing pharmaceutical products aimed at combating UTIs, a widespread medical condition in the US. The acquisition brings two key assets into Alembic's fold — 'Pivya,' an FDA-approved treatment for uncomplicated UTIs, and 'MEC,' a pipeline product currently under development to address complicated UTI cases. Alembic Pharmaceuticals sees this acquisition as a significant step towards strengthening its presence in the US market with branded specialty products. The deal allows Alembic to market Utility's assets in the US, leveraging the regulatory approvals already in place and continuing the development of promising pipeline therapies. The total consideration for the acquisition is expected to be around $12 million, paid in a staggered manner depending on the achievement of specific milestones. It also includes a provision for profit sharing based on future earnings generated by Utility's products. The transaction does not fall under the related party category, and none of the promoters or group companies have any financial interest in the deal. Completion of the acquisition is anticipated within approximately 30 days, and no additional regulatory approvals are required. This acquisition aligns with Alembic's strategy of expanding its global footprint and diversifying its product offerings in regulated markets like the US. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
